id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-319121-et957lfl	Mifflin, Lauren	Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target	2020-07-15		.txt	text/plain	12596	633	34	However, as researchers continued to delve into the mechanisms governed by RIPK1, it has become apparent that RIPK1 inhibitors may offer key therapeutic options that anti-TNF therapies do not: first, RIPK1 inhibitors are safe in the central nervous system (CNS) as RIPK1 kinase does not signal through TNFR2 which has a protective role in the CNS 7 ; second, RIPK1 participates in a broader set of pro-inflammatory activities than those restricted to TNF 8 ; third, RIPK1 is regulated by a distinct set of signalling molecules that are genetically implicated in human autoimmune and autoinflammatory diseases, as discussed below, and thus patient stratification may be important in conducting clinical trials of RIPK1 inhibitors. Mouse models with cell lineage-specific A20 deficiency phenocopy different human inflammatory diseases, suggesting an important role for A20 in restricting RIPK1 activation in multiple tissues ( showed increased levels of pro-inflammatory cytokines, such as TNF, IL-1β and IL-6, and demonstrated clinical improvement after treatment with anti-TNF or anti-IL-1β therapy.	./cache/cord-319121-et957lfl.txt	./txt/cord-319121-et957lfl.txt